Physician
Panhandle Eye Group, LLP
Panhandle Eye Group, LLP was paid $1.04M by Medicaid between Jan 2018 and Nov 2024, across 33 billing codes. Its largest line is J2778, Injection, ranibizumab, 0.1 mg — 29% of everything it billed.
33Billing provider infoPANHANDLE EYE GROUP, LLP
AMARILLO, TX 79106
AMARILLO, TX 79106
33aNPI1760571723assigned 10/11/2006
33bProvider typeOphthalmology Physician
28Total paid$1.04M
24GClaims37,530
24DCodes billed33
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ophthalmology Physician providers in Texas
Rank by total paid#7 of 231
Median peer was paid$16K
This provider vs. median66×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,487 | $169K | |
| 2019 | 6,880 | $233K | |
| 2020 | 4,441 | $161K | |
| 2021 | 6,211 | $191K | |
| 2022 | 5,110 | $96K | |
| 2023 | 4,450 | $115K | |
| 2024incomplete | 2,951 | $73K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg | 29% | 1,208 | 837 | $303K |
| J0178 | Injection, aflibercept, 1 mg | 16% | 463 | 330 | $162K |
| 67028 | Intravitreal injection of a pharmacologic agent | 12% | 6,098 | 4,218 | $124K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 10% | 4,631 | 4,459 | $106K |
| 92235 | 10% | 4,885 | 4,759 | $104K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 6.6% | 3,864 | 3,797 | $69K |
| 92134 | 5.2% | 4,228 | 4,099 | $54K | |
| 92250 | 3.4% | 2,603 | 2,534 | $35K | |
| J9035 | Injection, bevacizumab, 10 mg | 3.0% | 1,095 | 772 | $31K |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 2.6% | 62 | 39 | $27K |
| 92201 | 1.2% | 2,238 | 2,165 | $12K | |
| 92226 | <1% | 4,103 | 2,138 | $3K |
21 more codes
| 92202 | <1% | 640 | $2K | |
| 92020 | <1% | 453 | $2K | |
| 00142 | <1% | 46 | $948.27 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 51 | $741.71 |
| 92025 | <1% | 52 | $506.13 | |
| 92083 | <1% | 28 | $464.68 | |
| 92242 | <1% | 12 | $305.20 | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 12 | $287.71 |
| 92133 | <1% | 13 | $284.85 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 202 | $223.54 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $165.38 |
| CP003 | <1% | 16 | $156.80 | |
| 92136 | <1% | 25 | $156.70 | |
| 92145 | <1% | 120 | $135.48 | |
| 92285 | <1% | 13 | $106.45 | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 77 | $0.00 |
| 1036F | 0% | 69 | $0.00 | |
| G9367 | At least two orders for high-risk medications from the same drug class | 0% | 26 | $0.00 |
| G9366 | One high-risk medication not ordered | 0% | 15 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 138 | $0.00 |
| G9368 | At least two orders for high-risk medications from the same drug class not ordered | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARPENTER, CAROL (CEO)